||5R03CA103470-02 Interpret this number
||Group Health Cooperative
||Medical History, Medications, and Pancreatic Cancer Risk
DESCRIPTION (provided by applicant):
Risk factors for pancreatic cancer are not well established. The goal of this pilot study is to investigate the relation between medical history, medication use and pancreatic cancer in a case-control study based on medical record abstraction and electronic laboratory and pharmacy data.
Our specific aims are:
1. To investigate the relation between medical conditions and pancreatic cancer risk, focusing on:
a. Diabetes mellitus, including disease duration, therapy, and glycemic control.
b. Pancreatic inflammation, including acute and chronic pancreatitis.
c. History of peptic ulcer disease and/or infection with Helicobacter pylori (H. pylori).
d. History of cholecystectomy and/or cholelithiasis.
2. To investigate the relation between the use of medications and pancreatic cancer, focusing on nonsteroidal anti-inflammatory drugs, cholesterol lowering agents including HMG-CoA reductase inhibitors and acid suppressive medications including histamine receptor antagonists and proton pump inhibitors.
As a secondary specific aim we propose to examine additional medical conditions and medications in order to generate hypotheses for future studies of the epidemiology and prevention of pancreatic cancer. These include evaluation of medical conditions such as irritable bowel syndrome, allergies and asthma as well as medications including immunosuppressive medications and angiotensin converting enzyme inhibitors.
To meet these specific aims we propose to conduct a case-control study of pancreatic cancer comprised of 250 newly diagnosed cases and 1,000 controls in the defined population of Group Health Cooperative, a large health maintenance organization. Data on prior medical conditions and medications will be collected through abstraction of traditional and computerized medical records, including electronic laboratory and pharmacy data. Study strengths include the availability of uniformly collected, long-term medical and pharmacy data and the availability of data on important covariates, including smoking. The proposed study will provide a unique opportunity to investigate the role of medical conditions and medications in pancreatic tumorigenesis and to generate new insights into the mechanisms that result in pancreatic cancer.